menu
    • menu

    Company profile for Bridge Biotherapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Bridge Biotherapeutics, Inc. is a virtually-operated, venture-backed clinical stage global biotech company, headquartered in Seongnam, Korea with its subsidiary at JLABS@TMC, engaged in the development of novel therapeutics, focusing on therapeutic areas of high unmet medical needs, such as ulcerative colitis, fibrotic diseases, and cancers.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Bridge Biotherapeuticskorearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    Suite 903-2, Bldg B, Innovalley, 253 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeon...
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.bridgebiorx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Bridge Biotherapeutics to Present at J.P. Morgan Healthcare
    Bridge Biotherapeutics to Present at J.P. Morgan Healthcare

    30 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bridge-biotherapeutics-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302339220.html

    PR NEWSWIRE
    30 Dec 2024
    Share Share
    Bridge Biotherapeutics And HitGen Partner On Cancer Therapeutics
    Bridge Biotherapeutics And HitGen Partner On Cancer Therapeutics

    22 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bridge-biotherapeutics-and-hitgen-initiate-research-collaboration-to-advance-novel-cancer-therapeutics-program-302228404.html

    PR NEWSWIRE
    22 Aug 2024
    Share Share
    BridgeBio Launches GondolaBio With $300M, Transfers Programs
    BridgeBio Launches GondolaBio With $300M, Transfers Programs

    22 Aug 2024

    // BIOSPACE

    https://www.biospace.com/business/bridgebio-launches-gondolabio-with-300m-transfers-programs-to-joint-venture

    BIOSPACE
    22 Aug 2024
    Share Share
    Bridge Biotherapeutics Completes Enrollment For BBT-877 IPF Phase 2a Study
    Bridge Biotherapeutics Completes Enrollment For BBT-877 IPF Phase 2a Study

    29 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bridge-biotherapeutics-announces-completion-of-enrollment-in-the-phase-2a-clinical-study-of-bbt-877-for-the-treatment-of-idiopathic-pulmonary-fibrosis-302208799.html

    PR NEWSWIRE
    29 Jul 2024
    Share Share
    Bridge Collaboration with University to Explore Combination Therapy of BBT-877
    Bridge Collaboration with University to Explore Combination Therapy of BBT-877

    28 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bridge-biotherapeutics-launches-a-research-collaboration-with-emory-university-school-of-medicine-to-explore-combination-therapy-of-bbt-877-for-krasp53-mutant-nsclc-patients-resistant-to-anti-pd-1-blockade-302098969.html

    PR NEWSWIRE
    28 Mar 2024
    Share Share
    Bridge Announces Collaboration with University of Colorado to Explore BBT-877
    Bridge Announces Collaboration with University of Colorado to Explore BBT-877

    26 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bridge-biotherapeutics-announces-a-research-collaboration-with-the-university-of-colorado-school-of-medicine-to-explore-potential-of-bbt-877-for-immuno-oncology-302098937.html

    PR NEWSWIRE
    26 Mar 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search